Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
about
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaInvestigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data.Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.Anesthesia in a patient with gitelman syndromeThe role of concentration--effect relationships in the QTc interval prolongation: case sotalol.A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide
P2860
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
@ast
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
@en
type
label
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
@ast
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
@en
prefLabel
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
@ast
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
@en
P2860
P1476
Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP).
@en
P2093
James M Ritter
P2860
P304
P356
10.1111/J.1365-2125.2012.04193.X
P407
P577
2012-03-01T00:00:00Z